Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-19T16:53:54.727Z Has data issue: false hasContentIssue false

1057 – Evaluation Of Quality Of Life, Psychosocial Functioning, And Medication Adherence Among Patients Switched To Lurasidone From Other Antipsychotics

Published online by Cambridge University Press:  15 April 2020

G. Awad
Affiliation:
University of Toronto, Toronto, ON, Canada
M. Hassan
Affiliation:
Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA
A. Loebel
Affiliation:
Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA
J. Hsu
Affiliation:
Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA
A. Pikalov
Affiliation:
Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA
K. Rajagopalan
Affiliation:
Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Patient reported outcomes (PROs), i.e. quality of life (QoL), psychosocial functioning and medication adherence are vital assessments of results in schizophrenia treatment.

Objectives

Quality of life, psychosocial functioning and adherence attitude were evaluated among adult patients with schizophrenia switched from current antipsychotics to lurasidone, using the Personal Evaluation of Transitions in Treatment (PETiT) scale, a PRO measure.

Aims

Evaluate PROs after switching to lurasidone.

Methods

Stable but symptomatic adult outpatients with schizophrenia were switched from their previous antipsychotics to lurasidone, in a 6-week, open-label trial. Subjective responses to antipsychotic therapy were evaluated at baseline and study endpoint using PETiT (Higher scores=better outcomes). Score change was obtained for all patients and those switched from “sedating” (olanzapine, quetiapine) or “non-sedating” (risperidone, aripriprazole, ziprasidone, others) agents. Change from baseline to endpoint in total (overall QoL) and subscale scores (psychosocial functioning, adherence attitude) were compared using ANCOVA.

Results

Of the 244 patients switched to lurasidone, 213 had available data. Changes from baseline in mean total PETiT score (3.2, P< 0.0001) and subscale scores of psychosocial functioning (2.5) and adherence attitude (0.7) were reported in all patient groups (p< 0.001). Improvement in mean total PETiT score was observed in patients switched from non-sedating (3.5, n=139) and sedating (2.7, n=74) antipsychotics and was statistically significant (P< 0.0001) in the non-sedating group. Differences in statistical significance (sedating vs non-sedating) may arise from smaller changes, not sample size.

Conclusions

In this study, patients switching to lurasidone experienced improvement in QoL, psychosocial functioning and adherence attitude.

Type
Abstract
Copyright
Copyright © European Psychiatric Association 2013
Submit a response

Comments

No Comments have been published for this article.